1. Home
  2. JCE vs GALT Comparison

JCE vs GALT Comparison

Compare JCE & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Core Equity Alpha Fund of Beneficial Interest

JCE

Nuveen Core Equity Alpha Fund of Beneficial Interest

HOLD

Current Price

$15.81

Market Cap

269.8M

Sector

Finance

ML Signal

HOLD

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

HOLD

Current Price

$5.76

Market Cap

232.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JCE
GALT
Founded
2007
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
269.8M
232.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JCE
GALT
Price
$15.81
$5.76
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$6.00
AVG Volume (30 Days)
49.7K
376.2K
Earning Date
01-01-0001
11-14-2025
Dividend Yield
9.26%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.64
$0.73
52 Week High
$14.28
$6.55

Technical Indicators

Market Signals
Indicator
JCE
GALT
Relative Strength Index (RSI) 56.70 55.27
Support Level $15.22 $5.23
Resistance Level $15.76 $5.88
Average True Range (ATR) 0.25 0.51
MACD 0.01 -0.03
Stochastic Oscillator 83.48 52.87

Price Performance

Historical Comparison
JCE
GALT

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Share on Social Networks: